The chief medical officer of Genetix Biotherapeutics, formerly known as Bluebird bio, discusses timelines and operational ...

Four decades have passed since cochlear implants gave infants born deaf the ability to hear. Now, gene therapy promises to ...

The first study assessing the real-world commercial roll-out of gene therapies for sickle cell disease and beta thalassemia ...

Three years after introducing Hemgenix, the first gene therapy for hemophilia B, CSL Behring has released long-term data ...

Mixed headlines have plagued the cell and gene therapy space of late. We believe that a renewed case of optimism is not only ...

Gene therapy is a revolutionary field in modern medicine, offering transformative potential to treat and potentially cure a wide range of genetic and acquired diseases. By addressing the root cause of ...

About 100,000 people in the U.S. have sickle cell disease, a condition that primarily affects people of color, the CDC says.

Regeneron is adding its name to Tessera Therapeutics’ unique in vivo gene writing program, inking a deal that lets it in on a ...

Please refer to the ASH 2025 online program for full session details and visit the Genetix booth (#1261) onsite.

The 2025 Research Innovation Grants are supporting projects focused on biomarkers, risk factors, and treatments for ALS.

SCTbio , a leading European CDMO specializing in GMP manufacturing for cell-based products, and Fortrea , a leading global contract research organization (CRO), today announced a strategic ...

Regeneron Pharmaceuticals has teamed up with Tessera Therapeutics to develop and commercialise Tessera’s rare disease in vivo ...